Market Cap 248.94M
Revenue (ttm) 40.37M
Net Income (ttm) -119.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -296.56%
Debt to Equity Ratio 0.00
Volume 463,065
Avg Vol 696,282
Day's Range N/A - N/A
Shares Out 60.42M
Stochastic %K 81%
Beta 1.26
Analysts Strong Sell
Price Target $15.38

Company Profile

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neu...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 259 5340
Address:
75 Hayden Avenue, Lexington, United States
Orlandotrader
Orlandotrader May. 13 at 7:49 PM
$VYGR As the ‘Year of Tau’ for Alzheimer’s disease continues to unfold, Voyager looks forward to third-party data in mid-2026 that have the potential to confirm tau knockdown as the next critical approach to treating Alzheimer’s disease. Then, in the second half of the year, we expect first-in-human dosing of our tau silencing gene therapy VY1706 and tau PET imaging efficacy data for our anti-tau antibody VY7523,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “With our strong cash position of $172 million that is expected to provide runway into 2028, we continue to execute across our pipeline and platforms.”
0 · Reply
Orlandotrader
Orlandotrader May. 13 at 7:42 PM
$VYGR Big Things happen when the 50 and 200 come together. Hopeful of Positive Data .
0 · Reply
Orlandotrader
Orlandotrader May. 13 at 7:39 PM
$VYGR Tau works out and we FLY.
0 · Reply
OpenOutcrier
OpenOutcrier May. 13 at 12:18 PM
$VYGR (+5.5% pre) Voyager Therapeutics (VYGR) Reports Positive Findings for Alzheimer's Gene Therapy https://ooc.bz/l/102066
0 · Reply
DARKP00L
DARKP00L May. 13 at 10:10 AM
$VYGR 06:10 on May. 13 2026 Voyager Therapeutics' VY1706 Tau Silencing Gene Therapy Well Tolerated At Highest Dose, Reduces Tau Up To 64% In NHPs; Alzheimer's Clinical Trial Expected H2 2026 #tradeideas
0 · Reply
gookvook
gookvook May. 13 at 5:47 AM
1 · Reply
ivanhoff
ivanhoff May. 11 at 3:20 PM
Space stocks like $RKLB and $LUNR have been on fire in anticipation of SpaceX IPO next month. Lesser-knows space stocks like $VYGR might also get some buzz ahead and around that widely-expected IPO.
4 · Reply
tumanako
tumanako May. 11 at 10:08 AM
$VYGR Insitutional accumulations
0 · Reply
pickens1
pickens1 May. 8 at 2:59 PM
$VYGR Voyager reiterates a $172 million cash position providing runway into 2028.
0 · Reply
NorthStarStats
NorthStarStats Apr. 19 at 10:53 PM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. We aren't out of the wood yet. Be careful this coming week. $GPN Score 98, $MRNA Score 98, $SEIC Score 97, $VYGR Score 95, $VTGN Score 95
0 · Reply
Latest News on VYGR
Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)

2026-05-07T21:41:13.000Z - 5 days ago

Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)


Voyager Therapeutics management to meet with Oppenheimer

2026-04-28T12:55:45.000Z - 15 days ago

Voyager Therapeutics management to meet with Oppenheimer


Voyager Therapeutics management to meet with Oppenheimer

2026-04-10T20:55:57.000Z - 4 weeks ago

Voyager Therapeutics management to meet with Oppenheimer


Voyager Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 18, 2026, 12:30 PM EDT - 2 months ago

Voyager Therapeutics Transcript: Stifel 2026 Virtual CNS Forum


Voyager Therapeutics reports Q4 EPS (46c), consensus (51c)

2026-03-09T20:10:45.000Z - 2 months ago

Voyager Therapeutics reports Q4 EPS (46c), consensus (51c)


Voyager to Present at Upcoming Investor Conferences

Feb 9, 2026, 8:00 AM EST - 3 months ago

Voyager to Present at Upcoming Investor Conferences


Voyager Therapeutics files $400M mixed securities shelf

2025-11-10T21:10:18.000Z - 6 months ago

Voyager Therapeutics files $400M mixed securities shelf


Voyager Therapeutics reports Q3 EPS (47c), consensus (52c)

2025-11-10T13:17:23.000Z - 6 months ago

Voyager Therapeutics reports Q3 EPS (47c), consensus (52c)


Voyager Therapeutics expects cash to fund operations into 2028

2025-11-10T13:17:10.000Z - 6 months ago

Voyager Therapeutics expects cash to fund operations into 2028


Voyager Therapeutics reports Q2 EPS (57c), consensus (52c)

2025-08-06T20:33:20.000Z - 10 months ago

Voyager Therapeutics reports Q2 EPS (57c), consensus (52c)


Voyager Therapeutics continues expansion of its AD franchise

2025-07-16T11:06:32.000Z - 10 months ago

Voyager Therapeutics continues expansion of its AD franchise


Voyager Therapeutics reports Q1 EPS (53c), consensus (44c)

2025-05-06T20:11:39.000Z - 1 year ago

Voyager Therapeutics reports Q1 EPS (53c), consensus (44c)


Voyager Therapeutics Transcript: Virtual CNS Forum

Mar 19, 2025, 11:00 AM EDT - 1 year ago

Voyager Therapeutics Transcript: Virtual CNS Forum


Voyager Therapeutics Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Voyager Therapeutics Earnings Call Transcript: Q4 2024


Voyager Provides Update on SOD1 ALS Gene Therapy Program

Feb 11, 2025, 7:00 AM EST - 1 year ago

Voyager Provides Update on SOD1 ALS Gene Therapy Program


Voyager Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Voyager Therapeutics Earnings Call Transcript: Q3 2024


Voyager Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Voyager Therapeutics Earnings Call Transcript: Q2 2024


Voyager Therapeutics Earnings Call Transcript: Q1 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

Voyager Therapeutics Earnings Call Transcript: Q1 2024


Orlandotrader
Orlandotrader May. 13 at 7:49 PM
$VYGR As the ‘Year of Tau’ for Alzheimer’s disease continues to unfold, Voyager looks forward to third-party data in mid-2026 that have the potential to confirm tau knockdown as the next critical approach to treating Alzheimer’s disease. Then, in the second half of the year, we expect first-in-human dosing of our tau silencing gene therapy VY1706 and tau PET imaging efficacy data for our anti-tau antibody VY7523,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “With our strong cash position of $172 million that is expected to provide runway into 2028, we continue to execute across our pipeline and platforms.”
0 · Reply
Orlandotrader
Orlandotrader May. 13 at 7:42 PM
$VYGR Big Things happen when the 50 and 200 come together. Hopeful of Positive Data .
0 · Reply
Orlandotrader
Orlandotrader May. 13 at 7:39 PM
$VYGR Tau works out and we FLY.
0 · Reply
OpenOutcrier
OpenOutcrier May. 13 at 12:18 PM
$VYGR (+5.5% pre) Voyager Therapeutics (VYGR) Reports Positive Findings for Alzheimer's Gene Therapy https://ooc.bz/l/102066
0 · Reply
DARKP00L
DARKP00L May. 13 at 10:10 AM
$VYGR 06:10 on May. 13 2026 Voyager Therapeutics' VY1706 Tau Silencing Gene Therapy Well Tolerated At Highest Dose, Reduces Tau Up To 64% In NHPs; Alzheimer's Clinical Trial Expected H2 2026 #tradeideas
0 · Reply
gookvook
gookvook May. 13 at 5:47 AM
1 · Reply
ivanhoff
ivanhoff May. 11 at 3:20 PM
Space stocks like $RKLB and $LUNR have been on fire in anticipation of SpaceX IPO next month. Lesser-knows space stocks like $VYGR might also get some buzz ahead and around that widely-expected IPO.
4 · Reply
tumanako
tumanako May. 11 at 10:08 AM
$VYGR Insitutional accumulations
0 · Reply
pickens1
pickens1 May. 8 at 2:59 PM
$VYGR Voyager reiterates a $172 million cash position providing runway into 2028.
0 · Reply
NorthStarStats
NorthStarStats Apr. 19 at 10:53 PM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. We aren't out of the wood yet. Be careful this coming week. $GPN Score 98, $MRNA Score 98, $SEIC Score 97, $VYGR Score 95, $VTGN Score 95
0 · Reply
tumanako
tumanako Apr. 18 at 4:28 AM
$VYGR Buy and Buy.
0 · Reply
NorthStarStats
NorthStarStats Apr. 16 at 1:19 AM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. We're seeing renewed confidence in the market and excitement over earning seasons. $LEGN Score: 100, $MORN Score: 98, $SDGR Score: 98, $VYGR Score: 98, $TSLA Score: 98
0 · Reply
tumanako
tumanako Mar. 20 at 9:31 PM
$VYGR Investor Businss Daily identified as a cup with handle. What other stocks can you find such bullish pattern in today's market?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 20 at 6:31 PM
$VYGR RSI: 43.11, MACD: 0.0270 Vol: 0.40, MA20: 4.14, MA50: 3.92 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BiotechButterflies
BiotechButterflies Mar. 17 at 8:38 PM
$VYGR Ended 2025 with cash position of $202 million, expected to maintain runway into 2028.... and still has market cap of only about $250M... I know the science could be a long shot... but hey...
0 · Reply
Redposition
Redposition Mar. 17 at 7:25 PM
$VYGR It doesn't make sense !
1 · Reply
BigTimePennyStocks
BigTimePennyStocks Mar. 15 at 3:57 PM
Small-Caps with Catalysts this week: 👇👇 ( $ASBP, $XAIR, $VYGR, $GCTK, etc…) #NASDAQ #NYSE
1 · Reply
StockScanners
StockScanners Mar. 12 at 4:10 AM
$VYGR reached 5.48
0 · Reply
Chrissytina
Chrissytina Mar. 11 at 6:17 PM
$VYGR What happened 🤷🏼‍♀️ Why the dump this morning?
0 · Reply
LucyKent1972
LucyKent1972 Mar. 11 at 2:48 PM
$VYGR Gene therapy space remains highly speculative but interesting.
0 · Reply
Jrock618
Jrock618 Mar. 11 at 10:42 AM
$VYGR what’s actual price right now
0 · Reply